ArticleLipids in health and disease2022
Prevalence of dyslipidemia, treatment rate and its control among patients with type 2 diabetes mellitus in Northwest China: a cross-sectional study.
Article in Lipids in health and disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Worldwide Prevalence of Dyslipidemia in Diabetes: An Umbrella Overview of the Meta-Analysis StudiesEndocrine, metabolic & immune disorders drug targets · 2026Pooled it
- Trial
- Article
- Prevalence and risk factor analysis of early-onset dyslipidemia-a cross-sectional study of 3.7 million population.Lipids in health and disease · 2026Article
- Diabetic Dyslipidemia and Its Determinants Among People With Diabetes in South Africa: Protocol for a Systematic Review and Meta-Analysis.JMIR research protocols · 2026Article
- Article
- Article
- Article
- RAS-Related C3 Botulinum Toxin Substrate 1 Inhibition Attenuates Platelet Chemokine Activation in Diabetes Mellitus.Archives of Razi Institute · 2025Article
- Frequency and pattern of dyslipidemia and its association with other risk factors among Type-2 Diabetics.Pakistan journal of medical sciences · 2025Article
- Statin utilization and its predictors for the primary prevention of cardiovascular disease among type 2 diabetic patients in a resource-limited setting.Frontiers in endocrinology · 2025Article
- Chinese expert consensus on blood lipid management in patients with diabetes (2024 edition).Journal of translational internal medicine · 2024Article
- Lipid Disorders Management Strategies (2024) in Prediabetic and Diabetic Patients.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Evaluating Preferences of Hospitalized Diabetes Patients for Hospital-Wide Glycemic Control Programme: A Discrete Choice Experiment.Journal of diabetes research · 2024Article
- An ensemble model for predicting dyslipidemia using 3-years continuous physical examination data.Frontiers in physiology · 2024Article
- Association of the systemic immuno-inflammation index, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio with diabetic microvascular complications.Frontiers in endocrinology · 2024Article
- The association of dyslipidemia with kidney stone: result from the NHANES 2007-2020.International urology and nephrology · 2024Article
- Status of lipid control in Bangladeshi subjects with type 2 diabetes mellitus on lipid-lowering drugs: a multicenter, facility-based, cross-sectional study.BMC endocrine disorders · 2023Article
- Harnessing Code Interpreters for Enhanced Predictive Modeling: A Case Study on High-Density Lipoprotein Level Estimation in Romanian Diabetic Patients.Journal of personalized medicine · 2023Article
- High triglyceride levels increase the risk of diabetic microvascular complications: a cross-sectional study.Lipids in health and disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prevalence of cardiovascular disease (CVD) is high in China, especially in Northwest China, and dyslipidemia in diabetes is a major factor at risk for CVD. The dyslipidemia prevalence, treatment and control among type 2 diabetes mellitus (T2DM) patients in Northwest China were investigated.
methodsIn the cross-sectional retrospective research, 1386 medical records of T2DM patients were collected from the Endocrine Department of Tangdu Hospital. And patients' age, sex, diabetes duration, glycated hemoglobin (HbA1c), complications, lipid levels, and drug use were recorded. The patient characteristics, lipid level and lipid-lowering therapy were analyzed.
resultsIn this study, the dyslipidemia prevalence among T2DM patients was 87.7%, the treatment rate was 68.0%. The overall control rate of low-density lipoprotein cholesterol (LDL-C) was 43.1%, and control rates reached 52.7% for high-risk subjects and 36.1% for very high-risk subjects. The overall control rate of non-high-density lipoprotein cholesterol (non-HDL-C) was 19.8%. HbA1c (%) ≥ 7 was indicated as a major factor predicting failure of LDL-C and non-HDL-C control [odds ratio (OR) 1.521; 2.206, 95% confidence interval (CI) 1.154-2.005; 1.583-3.076)].
conclusionAmong patients with T2DM, it is high prevalence of dyslipidemia and low rate of treatment and control, and higher HbA1c level is the main factor for poor lipid control. It calls for more efforts to promote early screening, prevention and treatment of dyslipidemia for patients, thereby reducing the risk of CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.